Cite
HARVARD Citation
Schöffski, P. et al. (2019). Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'. Annals of oncology. p. 344. [Online].